Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

Inclusion Criteria: * Age between 18 and 70 years, male or female. * Histologically or cytologically confirmed malignant solid tumor that has relapsed or is refractory to standard therapy. * Subjects who have received prior radiation therapy with stable CNS metastasis with no progression of brain metastasis by CT/MRI scan in last 4 weeks. * Capable of providing informed consent and complying with trial procedures. * ECOG performance status 0-2. * Life expectancy \>12 weeks. * Measurable or evaluable disease according to RECIST 1.1 criteria. * Women must not be able to become pregnant (e.g. post menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. * Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating. * Geographic accessibility to the site. Exclusion Criteria: * Palliative surgery, chemotherapy, immunotherapy and/or radiation less than 4 weeks prior to the Screening Visit. * Exposure to any investigational agent within 30 days of the Screening Visit. * Laboratory values: Screening serum creatinine greater than or equal to 1.5 mg/dL, alanine aminotransferase (ALT) greater than 3 times the upper limit of normal, total bilirubin greater than 3 times the upper limit of normal, white blood cell (WBC) count \< 3500/mm3, absolute neutrophil count \< 2000/mm3, platelet concentration \< 100,000/mm3, hematocrit level \< 33% for females or \< 35% for males, or coagulation tests (PT,PTT) \>1.5 times the upper limit or normal. * Clinically evident congestive heart failure \> class II of the New York Heart Association (NYHA) guidelines. * Serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V. * History or signs of active coronary artery disease with or without angina pectoris. * Serious myocardial dysfunction defined scintigraphically (MUGA, myocardial scintigram)or ultrasound determined absolute left ventricular ejection fraction (LVEF) \< 45% of predicted. * History of HIV infection. * Active, clinically significant serious infection requiring treatment with antibiotics, antivirals or antifungals. * Major surgery within 3 weeks prior to treatment. * Substance abuse or any condition that might interfere with the subject's participation in the study or in the evaluation of the study results. * Any condition that is unstable and could jeopardize the subject's participation in the study.